Biocept Inc (BIOC) 2.60 $BIOC Biocept (BIOC): T
Post# of 64068
Posted On: 03/16/2015 1:35:34 PM
Biocept Inc (BIOC) 2.60 $BIOC
Biocept (BIOC): Today's Weak On High Volume Stock
at The Street - Fri Mar 13, 9:02AM CDT
Trade-Ideas LLC identified Biocept (BIOC) as a weak on high relative volume candidate
BIOC: 2.60 (-0.22)
Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations
GlobeNewswire - Tue Mar 10, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced the launch of its EGFR mutation detection testing utilizing a patient's blood-based liquid biopsy. This innovative diagnostic has the potential to help physicians identify which of their patients may be receptive to certain non-small cell lung cancer treatments.
BIOC: 2.60 (-0.22)
Biocept reports Q4 results
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 3:20PM CDT
BIOC: 2.60 (-0.22)
Biocept Reports Fourth Quarter 2014 Financial Results
GlobeNewswire - Mon Mar 09, 3:05PM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended December 31, 2014.
BIOC: 2.60 (-0.22)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 3.26 (-0.10), ONCY: 0.75 (-0.04), PLUG: 2.77 (-0.09), OCN: 8.69 (-0.68), XON: 45.68 (-0.81), TEDU: 10.45 (+0.11), BIOC: 2.60 (-0.22), LL: 29.16 (-1.39), MNKD: 5.47 (-0.04), CYCC: 1.00 (-0.05), CYTX: 1.32 (+0.12), DATE: 5.12 (-0.01), TSEM: 17.62 (+0.25), LEAF: 50.80 (+0.96), FNJN: 2.11 (+0.06), AMCO: 1.05 (+0.03)
Biocept to Present at the 27th Annual ROTH Conference
GlobeNewswire - Tue Mar 03, 7:31AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 27th Annual ROTH Conference on March 11, 2015 at The Ritz-Carlton Hotel in Laguna Niguel, California.
BIOC: 2.60 (-0.22)
Cost To Borrow Elevated On Biocept
Interactive Brokers - at Seeking Alpha - Mon Mar 02, 2:42PM CST
Cancer diagnostics company Biocept, Inc. (NASDAQ: BIOC ) has received a fair amount of attention in the securities lending space recently. As with similarly sized biotech companies (Biocept currently touts a market-cap of approximately $45mm), the...
BIOC: 2.60 (-0.22)
Most active Nasdaq-traded stocks
AP - Mon Mar 02, 12:17PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 28.30 (-0.42), BIOC: 2.60 (-0.22), ARCP: 9.84 (+0.12), MSFT: 41.38 (unch), INTC: 30.79 (-0.14), AAPL: 124.07 (+0.48), NSPH: 0.26 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 11:49AM CST
DRAM: 2.30 (-0.01), BIOC: 2.60 (-0.22), GTI: 3.94 (+0.03), TTI: 5.23 (-0.11), NXPI: 103.74 (-0.93), LL: 29.16 (-1.39), KOS: 8.05 (-0.09), CORE: 63.24 (+2.31), OMER: 24.11 (-1.10), DQ: 21.49 (-2.08), CYCC: 1.00 (-0.05), BORN: 1.13 (-0.02), AVEO: 1.30 (-0.10), SCMP: 18.29 (+0.45), BIOS: 4.24 (-0.01), OHRP: 9.46 (-0.25), MITL: 9.92 (-0.03), TCON: 14.80 (+1.05), PCRX: 95.71 (+2.81), NAVI: 19.65 (+0.37)
Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor
GlobeNewswire - Mon Mar 02, 7:35AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced that David Rimm, M.D., Ph.D., Professor of Pathology and Professor of Medicine in Medical Oncology at Yale University School of Medicine, will join the Company as a scientific advisor.
BIOC: 2.60 (-0.22)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 26.57 (+0.62), SLXP: 172.79 (+3.39), BIOC: 2.60 (-0.22), VASC: 28.97 (+0.01), AXPW: 0.11 (unch), FCCY: 11.82 (+0.10), RIGL: 3.39 (-0.21), REXI: 9.18 (-0.07), HLSS: 18.49 (-0.17)
Biocept (BIOC): Today's Weak On High Volume Stock
at The Street - Fri Mar 13, 9:02AM CDT
Trade-Ideas LLC identified Biocept (BIOC) as a weak on high relative volume candidate
BIOC: 2.60 (-0.22)
Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations
GlobeNewswire - Tue Mar 10, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced the launch of its EGFR mutation detection testing utilizing a patient's blood-based liquid biopsy. This innovative diagnostic has the potential to help physicians identify which of their patients may be receptive to certain non-small cell lung cancer treatments.
BIOC: 2.60 (-0.22)
Biocept reports Q4 results
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 3:20PM CDT
BIOC: 2.60 (-0.22)
Biocept Reports Fourth Quarter 2014 Financial Results
GlobeNewswire - Mon Mar 09, 3:05PM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended December 31, 2014.
BIOC: 2.60 (-0.22)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 3.26 (-0.10), ONCY: 0.75 (-0.04), PLUG: 2.77 (-0.09), OCN: 8.69 (-0.68), XON: 45.68 (-0.81), TEDU: 10.45 (+0.11), BIOC: 2.60 (-0.22), LL: 29.16 (-1.39), MNKD: 5.47 (-0.04), CYCC: 1.00 (-0.05), CYTX: 1.32 (+0.12), DATE: 5.12 (-0.01), TSEM: 17.62 (+0.25), LEAF: 50.80 (+0.96), FNJN: 2.11 (+0.06), AMCO: 1.05 (+0.03)
Biocept to Present at the 27th Annual ROTH Conference
GlobeNewswire - Tue Mar 03, 7:31AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 27th Annual ROTH Conference on March 11, 2015 at The Ritz-Carlton Hotel in Laguna Niguel, California.
BIOC: 2.60 (-0.22)
Cost To Borrow Elevated On Biocept
Interactive Brokers - at Seeking Alpha - Mon Mar 02, 2:42PM CST
Cancer diagnostics company Biocept, Inc. (NASDAQ: BIOC ) has received a fair amount of attention in the securities lending space recently. As with similarly sized biotech companies (Biocept currently touts a market-cap of approximately $45mm), the...
BIOC: 2.60 (-0.22)
Most active Nasdaq-traded stocks
AP - Mon Mar 02, 12:17PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 28.30 (-0.42), BIOC: 2.60 (-0.22), ARCP: 9.84 (+0.12), MSFT: 41.38 (unch), INTC: 30.79 (-0.14), AAPL: 124.07 (+0.48), NSPH: 0.26 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 11:49AM CST
DRAM: 2.30 (-0.01), BIOC: 2.60 (-0.22), GTI: 3.94 (+0.03), TTI: 5.23 (-0.11), NXPI: 103.74 (-0.93), LL: 29.16 (-1.39), KOS: 8.05 (-0.09), CORE: 63.24 (+2.31), OMER: 24.11 (-1.10), DQ: 21.49 (-2.08), CYCC: 1.00 (-0.05), BORN: 1.13 (-0.02), AVEO: 1.30 (-0.10), SCMP: 18.29 (+0.45), BIOS: 4.24 (-0.01), OHRP: 9.46 (-0.25), MITL: 9.92 (-0.03), TCON: 14.80 (+1.05), PCRX: 95.71 (+2.81), NAVI: 19.65 (+0.37)
Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor
GlobeNewswire - Mon Mar 02, 7:35AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced that David Rimm, M.D., Ph.D., Professor of Pathology and Professor of Medicine in Medical Oncology at Yale University School of Medicine, will join the Company as a scientific advisor.
BIOC: 2.60 (-0.22)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 26.57 (+0.62), SLXP: 172.79 (+3.39), BIOC: 2.60 (-0.22), VASC: 28.97 (+0.01), AXPW: 0.11 (unch), FCCY: 11.82 (+0.10), RIGL: 3.39 (-0.21), REXI: 9.18 (-0.07), HLSS: 18.49 (-0.17)
(0)
(0)